These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 23164748)

  • 41. Measurement of coronary fractional flow reserve. Standard doses of intracoronary adenosine are insufficient to induce maximal hyperaemia.
    Rzeczuch K; Jankowska E; Kaczmarek A; Telichowski A; Porada A; Banasiak W; Ponikowski P
    Kardiol Pol; 2003 Apr; 58(4):269-74. PubMed ID: 14517558
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Safety and feasibility of regadenoson use for suboptimal heart rate response during symptom-limited standard Bruce exercise stress test.
    Partington SL; Lanka V; Hainer J; Blankstein R; Skali H; Forman DE; Di Carli MF; Dorbala S
    J Nucl Cardiol; 2012 Oct; 19(5):970-8. PubMed ID: 22565239
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Acute myocardial infarction during regadenoson myocardial perfusion imaging.
    Shah S; Parra D; Rosenstein RS
    Pharmacotherapy; 2013 Jun; 33(6):e90-5. PubMed ID: 23471769
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Comparison of the myocardial blood flow response to regadenoson and dipyridamole: a quantitative analysis in patients referred for clinical 82Rb myocardial perfusion PET.
    Goudarzi B; Fukushima K; Bravo P; Merrill J; Bengel FM
    Eur J Nucl Med Mol Imaging; 2011 Oct; 38(10):1908-16. PubMed ID: 21656246
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Regadenoson, a selective A2A adenosine receptor agonist, causes dose-dependent increases in coronary blood flow velocity in humans.
    Lieu HD; Shryock JC; von Mering GO; Gordi T; Blackburn B; Olmsted AW; Belardinelli L; Kerensky RA
    J Nucl Cardiol; 2007 Jul; 14(4):514-20. PubMed ID: 17679059
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Ventricular Fibrillation Precipitated by Intracoronary Adenosine During Fractional Flow Reserve Assessment - A Cautionary Tale.
    Shah AH; Chan W; Seidelin PH
    Heart Lung Circ; 2015 Nov; 24(11):e173-5. PubMed ID: 26166173
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Safety and efficacy of a novel hyperaemic agent, intracoronary nicorandil, for invasive physiological assessments in the cardiac catheterization laboratory.
    Jang HJ; Koo BK; Lee HS; Park JB; Kim JH; Seo MK; Yang HM; Park KW; Nam CW; Doh JH; Kim HS
    Eur Heart J; 2013 Jul; 34(27):2055-62. PubMed ID: 23396491
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Regadenoson Stress Real-Time Myocardial Perfusion Echocardiography for Detection of Coronary Artery Disease: Feasibility and Accuracy of Two Different Ultrasound Contrast Agents.
    Abdelmoneim SS; Mulvagh SL; Xie F; O'Leary E; Adolphson M; Omer MA; Nhola LF; Huang R; Warta SJ; Kirby B; Porter TR
    J Am Soc Echocardiogr; 2015 Dec; 28(12):1393-400. PubMed ID: 26416199
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cardiac magnetic resonance perfusion imaging for the functional assessment of coronary artery disease: a comparison with coronary angiography and fractional flow reserve.
    Rieber J; Huber A; Erhard I; Mueller S; Schweyer M; Koenig A; Schiele TM; Theisen K; Siebert U; Schoenberg SO; Reiser M; Klauss V
    Eur Heart J; 2006 Jun; 27(12):1465-71. PubMed ID: 16720685
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Intracoronary adenosine-induced ventricular arrhythmias during fractional flow reserve (FFR) measurement: case series and literature review.
    Patel HR; Shah P; Bajaj S; Virk H; Bikkina M; Shamoon F
    Cardiovasc Interv Ther; 2017 Oct; 32(4):374-380. PubMed ID: 27577946
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A population pharmacokinetic/pharmacodynamic analysis of regadenoson, an adenosine A2A-receptor agonist, in healthy male volunteers.
    Gordi T; Frohna P; Sun HL; Wolff A; Belardinelli L; Lieu H
    Clin Pharmacokinet; 2006; 45(12):1201-12. PubMed ID: 17112296
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Myocardial Stress Perfusion MRI: Experience in Pediatric and Young-Adult Patients Following Arterial Switch Operation Utilizing Regadenoson.
    Noel CV; Krishnamurthy R; Masand P; Moffett B; Schlingmann T; Cheong BY; Krishnamurthy R
    Pediatr Cardiol; 2018 Aug; 39(6):1249-1257. PubMed ID: 29748700
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Regadenoson and adenosine are equivalent vasodilators and are superior than dipyridamole- a study of first pass quantitative perfusion cardiovascular magnetic resonance.
    Vasu S; Bandettini WP; Hsu LY; Kellman P; Leung S; Mancini C; Shanbhag SM; Wilson J; Booker OJ; Arai AE
    J Cardiovasc Magn Reson; 2013 Sep; 15(1):85. PubMed ID: 24063278
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Regadenoson in the detection of coronary artery disease.
    Buhr C; Gössl M; Erbel R; Eggebrecht H
    Vasc Health Risk Manag; 2008; 4(2):337-40. PubMed ID: 18561509
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Daily Caffeine Consumption Is Associated with Decreased Incidence of Symptoms and Hemodynamic Changes During Pharmacologic Stress with Regadenoson.
    Posch MI; Kay MD; Harhash AA; Huang JJ; Krupinski EA; Abidov A; McMillan NA; Kuo PH
    J Nucl Med Technol; 2020 Mar; 48(1):73-76. PubMed ID: 31604901
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Role of incremental doses of intracoronary adenosine for fractional flow reserve assessment.
    Murtagh B; Higano S; Lennon R; Mathew V; Holmes DR; Lerman A
    Am Heart J; 2003 Jul; 146(1):99-105. PubMed ID: 12851614
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Metoprolol does not effect myocardial fractional flow reserve in patients with intermediate coronary stenoses.
    Ozdemir M; Yazici GE; Turkoglu S; Timurkaynak T; Cengel A
    Int Heart J; 2007 Jul; 48(4):477-83. PubMed ID: 17827819
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Detection of coronary stenosis with myocardial contrast echocardiography using regadenoson, a selective adenosine A2A receptor agonist.
    Le DE; Bragadeesh T; Zhao Y; Wang YG; Zha D; Kaul S
    Eur Heart J Cardiovasc Imaging; 2012 Apr; 13(4):298-308. PubMed ID: 22067143
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Assessment of increasing intravenous adenosine dose in fractional flow reserve.
    Sparv D; Götberg M; Harnek J; Persson T; Madsen Hardig B; Erlinge D
    BMC Cardiovasc Disord; 2017 Feb; 17(1):60. PubMed ID: 28196527
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Regadenoson pharmacokinetics and tolerability in subjects with impaired renal function.
    Gordi T; Blackburn B; Lieu H
    J Clin Pharmacol; 2007 Jul; 47(7):825-33. PubMed ID: 17585115
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.